Evidence map›Paper›PMID 32994806›Full record

ArticleTherapeutic advances in medical oncology2020

Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup.

Julius Emons, Peter A Fasching, Marius Wunderle, Felix Heindl, Jens Rieger, Florian Horn, Georg Pelzer, Andre Ritter, Thomas Weber, Marcus Radicke and 10 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Hard X-ray omnidirectional differential phase and dark-field imaging.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Julius EmonsDepartment of Gynecology and Obstetrics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Universitätsstrasse 21-23, Erlangen 91054, Germany.
Marius WunderleDepartment of Gynecology and Obstetrics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Felix HeindlDepartment of Gynecology and Obstetrics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Jens RiegerErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Florian HornErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Georg PelzerErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Andre RitterErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Thomas WeberErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Marcus RadickeSiemens Healthcare GmbH, Erlangen, Germany.
Iris PolifkaInstitute of Pathology, Erlangen University Hospital, Erlangen, Germany.
David L WachterInstitute of Pathology, Erlangen University Hospital, Erlangen, Germany.
Evelyn WenkelInstitute of Diagnostic Radiology, Erlangen University Hospital, Erlangen, Bayern, Germany.
Thilo MichelErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Michael UderInstitute of Diagnostic Radiology, Erlangen University Hospital, Erlangen, Bayern, Germany.
Arndt HartmannInstitute of Pathology, Erlangen University Hospital, Erlangen, Germany.
Gisela AntonErlangen Center for Astroparticle Physics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Rüdiger Schulz-WendtlandInstitute of Diagnostic Radiology, Erlangen University Hospital, Erlangen, Bayern, Germany.
Sebastian M JudDepartment of Gynecology and Obstetrics, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Bayern, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversitätsklinikum Erlangen · DEBayer (Germany) · DEComprehensive Cancer Center Erlangen · DESiemens Healthcare (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMammography can identify calcifications up to 50-100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma

methodsTalbot-Lau X-ray phase-contrast imaging and X-ray dark-field imaging were used to acquire images of breast specimens. The radiation dosage with the technique is comparable with conventional mammography. Three X-ray gratings with periods of 5-10 µm between the X-ray tube and the flat-panel detector provide three different images in a single sequence: the conventional attenuation image, differential phase image, and dark-field image. The images were read by radiologists. Radiological findings were marked and examined pathologically. The results were described in a descriptive manner.

resultsA total of 81 breast specimens were investigated with the two methods; 199 significant structures were processed pathologically, consisting of 123 benign and 76 malignant lesions (DCIS or invasive breast cancer). X-ray dark-field imaging identified 15 additional histologically confirmed carcinoma lesions that were visible but not declared suspicious on digital mammography alone. Another four malignant lesions that were not visible on mammography were exclusively detected with X-ray dark-field imaging.

conclusionsAdding X-ray dark-field imaging to digital mammography increases the detection rate for breast cancer and DCIS associated lesions with micrometer-sized calcifications.The use of X-ray dark-field imaging may be able to provide more accurate and detailed radiological classification of suspicious breast lesions.Adding X-ray dark-field imaging to mammography may be able to increase the detection rate and improve preoperative planning in deciding between mastectomy or breast-conserving therapy, particularly in patients with invasive lobular breast cancer.

Indexed as

breast cancerinterferometrymammographymicrocalcifications

Identifiers

PMID32994806
PMCPMC7502853
OpenAlexW3087229871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.